|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.350 USD | 0.00% |
|
+4.65% | -61.76% |
| 06-30 | ADC Therapeutics SA Completes Enrollment In LOTIS-7 Phase 1b ZYNLONTA Combination Trial | CI |
| 06-30 | ADC Therapeutics Completes Enrollment in LOTIS-7 Lymphoma Study | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 172M | - | - | - | ||
| 52.1B | |||||
| 53.83B | |||||
| 23.48B | - | ||||
| 23.13B | - | ||||
| 19.36B |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
